Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.
The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative…
Adding olaparib to bevacizumab was safe with good quality of life in older patients with advanced ovarian cancer.
Researchers found an association between cardiovascular disease and more advanced stage of breast cancer at diagnosis, “independent of factors associated with delayed diagnosis and shared…
Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether…
JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.
